Desire: what the research says about PT-141
PT-141: Melanocortin agonist studied for low sexual desire; the active ingredient in the FDA-approved Vyleesi.
Desire from USA Standard Research: nasal spray, PT-141 10 mg per 10 mL bottle. Sold for research use only.
Editorial discussion starter: which finding would you like explained, and what does the research leave open? Share public sources. Please leave out personal medical details and dosing.
The research
PT-141 (bremelanotide)
Melanocortin agonist studied for low sexual desire; the active ingredient in the FDA-approved Vyleesi.
Human trials for a specific indication
What it is studied for
Bremelanotide has been studied for persistently low sexual desire that causes distress. Vyleesi’s studies assessed changes in desire and related distress in a defined patient group. Earlier small studies tested a nasal form in men with erectile dysfunction and in women with sexual arousal disorder.
What the evidence says
The approval is specific to Vyleesi and its indication; it does not cover every PT-141 formulation. The label excludes general sexual-performance enhancement and lists nausea and temporary blood-pressure increases among important risks. In two 24-week phase 3 trials of 1,267 women, desire scores rose 0.3 to 0.4 points more than with placebo on a 1.2 to 6 scale, with more nausea, flushing and headache.
Desire
- Nasal spray PT-141 10 mg per 10 mL bottle
Sold by USA Standard Research, the team behind PeptidesGenie, for research use only. Not for human or veterinary use.
Research cited
- 1Vyleesi prescribing information US prescription label
- 2Diamond et al. (2004): Intranasal PT-141 in healthy men and men with erectile dysfunction Small randomized human trial (phase 1)
- 3Diamond et al. (2006): Intranasal bremelanotide in premenopausal women with sexual arousal disorder Small randomized human trial
- 4Kingsberg et al. (2019): Bremelanotide for hypoactive sexual desire disorder, two randomized phase 3 trials Randomized human trials (phase 3)